Good afternoon everyone and thank you for coming. My name is Ms. Valerie and I'm member of the semiconductor and capital equipment equity research team here at Morgan Stanley. It's my pleasure to welcome Martin Headley, CFO of Brooks Automation. Martin is going to kick us off with some high level comments, opportunities for 2012 and then we'll jump into some Q&A. Martin Headley Thank you very much. I think it's best to frame what's top of mind with Brooks by maybe five significant priorities that we have at the moment. Firstly its integrating our new and very exciting Brooks Life Science Systems business into Brooks. This is a business that we entered with the acquisitions of RTF Life Sciences and Nexus Bio Systems during the course of 2011 and followed up with a very exciting product line acquisition of an automated Cytometer called Celigo in December of 2011 and this is a business that we see having a growth potential of over 20% per annum driven by personalized medicine initiatives that are really expanding the amount of biological samples that are being stored on this earth to facilitate those initiatives and we see the amount of samples being stored growing at somewhere between 25% and 30% per year and really being the fuel behind the driver for a fully effective sample management solution that will enable a better yield of the samples available from storage.